Evidence map›Paper›PMID 42560040›Full record

ArticleBioinformatics (Oxford, England)2026

MARD-Mol: a hybrid autoregressive-diffusion paradigm for coarse-grained molecular modeling.

Sizhe Zhang, Gang Luo, Wei Fan, Xiaoyi Lv, Min Li

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sizhe ZhangSchool of Computer Science and Engineering, Central South University, Changsha, 410083, China.
Gang LuoSchool of Computer Science and Engineering, Central South University, Changsha, 410083, China.
Wei FanSchool of Computer Science, University of Auckland, Auckland, 1010, New Zealand.
Xiaoyi LvSchool of Software, Xinjiang University, Urumqi, 830091, China.ORCID 0000-0001-6855-7428
Min LiSchool of Computer Science and Engineering, Central South University, Changsha, 410083, China.ORCID 0000-0002-0188-1394

Funding

Hunan Provincial Natural Science Foundation 2025JJ30025
6 · The paper itself

Abstract

motivationDeep generative models have transformed drug molecule generation. However, molecules exhibit complex hierarchical structures, requiring models to simultaneously balance macroscopic topological coherence and microscopic chemical self-consistency. Although autoregressive (AR) and discrete diffusion paradigms are highly complementary, integrating their advantages within a unified architecture remains severely limited by traditional "atom-by-atom" fine-grained modeling.

resultsWe propose MARD-Mol, a hybrid AR-diffusion framework based on motif-inspired units. By elevating the representation granularity from atoms to motif-inspired units and introducing a dual-stream hierarchical attention mechanism, it couples inter-unit AR global scaffold planning with intra-unit discrete diffusion generation. To support goal-directed drug discovery, we reformulate property optimization into an iterative "diagnose-and-repair" process, enabling targeted optimization of defective motifs while preserving the global scaffold. Extensive experiments demonstrate that MARD-Mol achieves an 86.0% Quality score in de novo generation and exhibits superior performance in fragment-constrained and multi-objective optimization, establishing a new paradigm for high-quality drug design. AVAILABILITY AND IMPLEMENTATION: The source code and datasets used in this study are available at GitHub: https://github.com/CSUBioGroup/MARD-Mol.

Indexed as

Computational BiologyDrug DiscoveryModels, MolecularSoftwareAlgorithmsDiffusionDrug Design

Identifiers

PMID42560040
PMCPMC13489711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.